Sa1923 Histological Findings of Intestinal Metaplasia in the Gastric Corpus Is a Predictive Factor for the Development of Gastric Cancer

G A A b st ra ct s NRAS (N = 51), significantly shorter progression free survival (PFS) [median (month): 2.6 vs. 7.7; hazard ration (HR): 0.25; 95% confidence interval (CI): 0.12-0.525; P = 0.0003] were observed in CRCs with at least one mutation of KRAS, BRAF, PIK3CA, and NRAS (N = 17); however, no significant difference in overall survival (OS) (P = 0.93) was observed between them. High miR-31 expression was significantly associated with shorter PFS [median (month): 2.6 vs. 6.2; HR: 0.36; 95% CI: 0.17-0.69; P = 0.004] and OS [median (month): 4.7 vs. 11.2; HR: 0.49; 95% CI: 0.27-0.94; P = 0.034], respectively. In contrast, none of other miRNAs was associated with the efficacy of anti-EGFR therapy in metastatic CRC. Conclusion: High miR-31 expression was related with the resistance to anti-EGFR agents among patients with CRC. This association was more significant compared with combination analysis of gene mutations in the EGFR downstream pathway. Thus, our data suggest that miR-31 may be a useful biomarker for anti-EGFR therapy in metastatic CRC.